Abstract
Apolipoprotein D (apoD) is an atypical plasma apolipoprotein and, based on its primary structure, it is a member of the lipocalin protein superfamily. Lipocalins have been extensively used as disease markers and, accordingly, apoD has become increasingly recognized as an important factor in the pathology of human neurodegenerative and neuropsychiatric disorders. ApoD expression is increased in the plasma and brains of subjects with schizophrenia and bipolar disorder, suggesting that it acts as a marker for disease pathology. ApoD also exhibits complex regulation by antipsychotic drug treatment and may represent a distinguishing mechanism of typical versus atypical drugs. The precise role of apoD in the CNS and disease remains to be elucidated, but recent findings have suggested that it plays an important role in the regulation of arachidonic acid signaling and metabolism providing further support for phospholipid membrane pathology in schizophrenia.
Keywords: pharmacotherapy, pathophysiology, apolipoprotein d, psychiatric disorders, lipocalin protein superfamily
Current Molecular Medicine
Title: From Pharmacotherapy to Pathophysiology: Emerging Mechanisms of Apolipoprotein D in Psychiatric Disorders
Volume: 3 Issue: 5
Author(s): E. A. Thomas, D. L. Copolov and J. G. Sutcliffe
Affiliation:
Keywords: pharmacotherapy, pathophysiology, apolipoprotein d, psychiatric disorders, lipocalin protein superfamily
Abstract: Apolipoprotein D (apoD) is an atypical plasma apolipoprotein and, based on its primary structure, it is a member of the lipocalin protein superfamily. Lipocalins have been extensively used as disease markers and, accordingly, apoD has become increasingly recognized as an important factor in the pathology of human neurodegenerative and neuropsychiatric disorders. ApoD expression is increased in the plasma and brains of subjects with schizophrenia and bipolar disorder, suggesting that it acts as a marker for disease pathology. ApoD also exhibits complex regulation by antipsychotic drug treatment and may represent a distinguishing mechanism of typical versus atypical drugs. The precise role of apoD in the CNS and disease remains to be elucidated, but recent findings have suggested that it plays an important role in the regulation of arachidonic acid signaling and metabolism providing further support for phospholipid membrane pathology in schizophrenia.
Export Options
About this article
Cite this article as:
Thomas A. E., Copolov L. D. and Sutcliffe G. J., From Pharmacotherapy to Pathophysiology: Emerging Mechanisms of Apolipoprotein D in Psychiatric Disorders, Current Molecular Medicine 2003; 3 (5) . https://dx.doi.org/10.2174/1566524033479681
DOI https://dx.doi.org/10.2174/1566524033479681 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Kynurenine 3-Monooxygenase (KMO): Implications for Therapy in Huntingtons Disease
CNS & Neurological Disorders - Drug Targets Literature Evidence and ARRIVE Assessment on Neuroprotective Effects of Flavonols in Neurodegenerative Diseases' Models
CNS & Neurological Disorders - Drug Targets Stress-Induced Oxidative Changes in Brain
CNS & Neurological Disorders - Drug Targets The Prospect of Stem Cells as Multi-Faceted Purveyors of Immune Modulation, Repair and Regeneration in Multiple Sclerosis
Current Stem Cell Research & Therapy Systematic Evaluation of Drug-Loaded Hydrogels for Application in Osteosarcoma Treatment
Current Pharmaceutical Biotechnology Repurposing Antihypertensive Drugs for the Management of Alzheimer’s Disease
Current Medicinal Chemistry Nicotinic Receptors and the Treatment of Attentional and Cognitive Deficits in Neuropsychiatric Disorders: Focus on the α7 Nicotinic Acetylcholine Receptor as a Promising Drug Target for Schizophrenia
Central Nervous System Agents in Medicinal Chemistry The Role of Amyloid-Beta Derived Diffusible Ligands (ADDLs) in Alzheimers Disease
Current Topics in Medicinal Chemistry Current Opinion on 3-[2-[(2-Tert-Butyl-Phenylaminooxalyl)-Amino]-Propionylamino]- 4-Oxo-5-(2,3,5,6-Tetrafluoro-Phenoxy)-Pentanoic Acid, an Investigational Drug Targeting Caspases and Caspase-Like Proteases: The Clinical Trials in Sight and Recent Anti-Inflammatory Advances
Recent Patents on Inflammation & Allergy Drug Discovery Phosphodiesterase 10 Inhibitors: New Disease Modifying Drugs for Parkinson’s Disease?
Current Medicinal Chemistry Bridge Between Neuroimmunity and Traumatic Brain Injury
Current Pharmaceutical Design Potential Therapeutic Relevance of Adenosine A2B and A2A Receptors in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Meet the Editorial Board:
Technology Transfer and Entrepreneurship (Discontinued) A Urinary Metabolomics Analysis Based on UPLC-MS and Effects of Moxibustion in APP/PS1 Mice
Current Alzheimer Research Bitropic D3 Dopamine Receptor Selective Compounds s Potential Antipsychotics
Current Pharmaceutical Design Glutamate Receptors in Human Caudate Nucleus in Normal Aging and Alzheimer’s Disease
Current Alzheimer Research Hepatocyte Growth Factor (HGF): Neurotrophic Functions and Therapeutic Implications for Neuronal Injury/Diseases
Current Signal Transduction Therapy Strength and Weaknesses of Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease and Possible Detection of Overlaps with Frailty Process
CNS & Neurological Disorders - Drug Targets Cognitive Decline as a Consequence of Essential Hypertension
Current Pharmaceutical Design Modulation of Mitochondrial Permeability Transition in Ischemia-Reperfusion Injury of the Heart. Advantages and Limitations
Current Medicinal Chemistry